Untitled Document Page 1 of 2

Virginia AIDS Drug Assistance Program Updates

AIDS DRUG ASSISTANCE PROGRAM (ADAP) UPDATE !!!!! (as of October 2007)

ADAP UPDATE!!

The following medications have been added to the ADAP formulary effective October 2007:

Entry Inhibitor (CCR5 co-receptor antagonist)

Maraviroc (**Selzentry**) Exception Criteria: NRTI and NNRTI experienced or contraindicated and prior experience with 1 or more PIs with a positive blood test for the CCR5 co-receptor test within 3 months. *Medication Exception Form required* only with the *initial* prescription. This is a **new** class of antiretrovirals.

Antilipidemics:

rosuvastatin (Crestor)

Antianxiety Agents

buspirone (**BuSpar**) hydroxyzine (**Atarax**)

Antidepressants

amitriptyline (Elavil)
bupropion (Wellbutrin)
citalopram (Celexa)
doxepin (Sinequan)
duloxetine (Cymbalta)
escitalopram (Lexapro)
fluoxetine (Prozac)
mirtazapine (Remeron)
nortriptyline (Pamelor)
paroxetine (Paxil)
sertraline (Zoloft)
trazodone (Desyrel)
venlafaxine (Effexor)

Antipsychotic Agents

chlorpromazine (**Thorazine**) haloperidol (**Haldol**) olanzapine (**Zyprexa**) risperidone (**Risperdal**) ziprasidone (**Geodon**)

Bipolar Agents

lithium (Eskalith)

Note: Clients who have participated in a maraviroc clinical trial or expanded access program will be eligible to receive the medication. Clinicians will need to indicate study participation under "Reason for Exception" on the ADAP Medication Exception Form.

Archive of Past Updates

Untitled Document Page 2 of 2

May 2007 (pdf)

Take Me To The ADAP Homepage

Questions or comments?

Contact HIV/STD/Viral Hepatitis Hotline